KUALA LUMPUR (Jan 20): INIX Technologies Holdings Bhd is taking legal action against The Edge on the article titled “INIX Technologies application to supply Covid-19 vaccines yet to be received by NPRA”.
In a bourse filing, the company said that the article published today was a misleading and damaging statement.
“INIX Technologies Holdings Bhd has instructed its lawyer to seek appropriate legal recourse which shall include a demand from the author and the publisher of the article to retract the misleading and damaging statement and to publish an appropriate apology and clarification.
"The company will also seek an undertaking that the author and publisher of the article shall not repeat the statements in any form. In the meantime, the company shall reserve all the rights whatsoever,” it said.
The Edge has received the legal letter from INIX on the matter this afternoon.
The legal letter claimed that INIX made its application to the National Pharmaceutical Regulatory (NPRA) on Jan 12, 2021.
To recap, on Jan 13, INIX announced to Bursa Malaysia that it had submitted its application for the registration of the vaccines — which will be supplied by Sinovac Biotech Co Ltd, CanSino Biologics Inc and Sinopharm China National Biotech Group Co Ltd.
When contacted by The Edge to seek clarification on the matter, Health Director-General Tan Sri Dr Noor Hisham Abdullah said there has been no application yet from INIX.
The only company that has thus far received conditional registration from the NPRA for its Covid-19 vaccine is Pfizer, as updated by Science, Technology and Innovation Minister Khairy Jamaluddin last week.
At the time of writing, shares in INIX gained 6.35% or two sen to 33.5 sen, valuing it at RM156.31 million. It saw 16.79 million shares traded.